X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/waylivra-receives-innovative-drug-category-pricing-to-treat-familial-chylomicronemia-syndrome-in-brazil-301453143.html
https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-waylivra-approval-in-brazil-as-first-treatment-for-familial-chylomicronemia-syndrome-301360828.html
https://pharmaphorum.com/news/nice-relents-and-okays-akceas-rare-disease-drug-waylivra-for-nhs-use/
https://www.businesswire.com/news/home/20200918005029/en/WAYLIVRA%E2%96%BC%C2%AE-volanesorsen-the-First-and-Only-Therapy-for-FCS-an-Ultra-Rare-and-Life-Threatening-Condition-to-Be-Available-on-the-NHS-in-England
http://www.pharmatimes.com/news/nice_u-turn_sees_akceas_waylivra_win_nhs_funding_1350842
https://www.prnewswire.com/news-releases/akcea-announces-new-pricing-and-reimbursement-of-waylivra-volanesorsen-in-germany-301111204.html
https://www.globenewswire.com/news-release/2020/01/09/1968558/0/en/Retrotope-Expands-its-Drug-Pipeline-with-the-First-Dosing-of-RT001-in-patients-with-Friedreich-s-ataxia-FA.html
http://www.pharmatimes.com/news/nice_refuses_akceas_waylivra_1321285
https://www.fiercepharma.com/marketing/akcea-taps-first-chief-commercial-officer-as-waylivra-debuts-and-pipeline-advances
https://www.contractpharma.com/contents/view_breaking-news/2019-10-24/akcea-therapeutics-appoints-chief-commercial-officer/
https://www.fiercebiotech.com/biotech/ionis-cbo-takes-over-akcea-as-ceo-cbo-and-coo-head-out-door
https://www.fiercepharma.com/pharma/rejected-by-fda-ionis-and-akcea-s-waylivra-finds-new-life-eu-approval
https://www.xconomy.com/san-diego/2018/08/27/fda-gives-thumbs-down-to-rare-disease-drug-from-ionis-akcea/
http://www.pharmatimes.com/news/fda_rejects_akceaionis_rare_disease_drug_waylivra_1250346
https://www.fiercebiotech.com/biotech/fda-nixes-akcea-s-volanesorsen-despite-favorable-adcomm
https://www.bizjournals.com/boston/news/2018/08/27/fda-rejects-rare-liver-disease-drug-developed-by.html
https://www.prnewswire.com/news-releases/ionis-htt-rx-rg6042-granted-prime-designation-by-the-european-medicines-agency-for-the-treatment-of-people-with-huntingtons-disease-300691421.html
https://www.prnewswire.com/news-releases/akcea-therapeutics-and-ptc-therapeutics-collaborate-to-commercialize-two-rare-disease-drugs-in-latin-america-300690950.html
https://www.prnewswire.com/news-releases/ionis-closes-strategic-collaboration-with-biogen-to-develop-drugs-for-a-broad-range-of-neurological-diseases-300660168.html
https://endpts.com/akcea-ionis-win-over-most-fda-experts-to-its-rare-disease-drug-volanesorsen-vastly-improving-odds-of-success/
https://www.fiercebiotech.com/biotech/astellas-to-pay-aquinox-25m-upfront-for-regional-rights-to-phase-3-inflammatory-pain-drug
https://endpts.com/ionis-akcea-team-face-some-tough-questions-on-safety-as-fda-insiders-ponder-risks-linked-to-volanesorsen/
https://endpts.com/swapping-stock-and-cash-ionis-turns-to-closely-controlled-akcea-for-a-deal-on-spurned-drug-inotersen/
Market Place
Share 
